PDCD1 and hepatocellular carcinoma: Anti-angiogenic drugs, such as tyrosine kinase inhibitors (TKIs), combined with immunotherapies (e.g., programmed cell death protein 1 [PD-1]) have become an important choice for unresectable or intermediate and advanced HCC, and for conversion therapy of potentially resectable HCC (7).